What Бараклюд Treats: Main Uses and Benefits

Бараклюд (Entecavir) is commonly used for the long-term management of persistent infection caused by the Hepatitis B Virus (HBV). It is applied in clinical settings to address the progression of liver disease driven by active viral replication.

The medicine is used to treat chronic hepatitis B in adults and in children from two years of age, particularly when there is evidence of active liver injury. It is commonly used for patients who show clear evidence of the virus actively multiplying, covering both HBeAg-positive and HBeAg-negative disease classifications.

The medication is applied in addressing key therapeutic domains, including active chronic viral replication, the mitigation of liver damage, and the management of active disease present alongside compensated and decompensated liver cirrhosis. In these contexts, the medicine helps to reduce elevated liver enzyme markers and supports the patient in maintaining a sense of stability when symptoms are more noticeable.

“This antiviral management supports the patient's long-term health by addressing the chronic viral presence that drives progressive liver injury.”

This targeted approach contributes to easing the overall symptom load and is applicable in scenarios where the patient requires assistance with sustained viral suppression and reduced risk of long-term complications.

---

Quick Fact: Relief for Chronic Liver Strain

Property	Description
Primary Domain	Management of Chronic HBV Infection
Symptom Axis	Symptoms linked to organ-specific functional stress
Clinical Context	Applied in scenarios requiring sustained viral suppression
Key Benefit	Supports long-term disease management and improved clinical stability

Regulatory References

1. European Medicines Agency therapeutic overview

Бараклюд (Entecavir) eligibility is determined by specific rules outlined in official regulatory documents regarding patient age, pre-existing conditions, and physiological status.

Official Eligibility and Exclusion Rules

Category	Eligibility Status as per Regulatory Label
Absolute Contraindication	Patients with a known hypersensitivity to entecavir or any component of the formulation must not use the medicine.
Approved Age Group	The medicine is approved for adults and pediatric patients who are mathbf2 years of age and older.
Pediatric Restriction	Use is not established or not recommended in children younger than two years of age or those weighing less than 10 kg.
Conditional Use (Renal)	Patients with renal impairment (creatinine clearance < 50 mL/min), including those on haemodialysis, are eligible but require official dosage adjustment.
Co-Infection Status	The medicine is not recommended for patients co-infected with HIV and HBV who are not also receiving a fully suppressive Highly Active Antiretroviral Therapy (HAART).
Pregnancy and Lactation	Use during pregnancy is generally not recommended unless the potential benefit justifies the potential risk. Breastfeeding must be discontinued during treatment.

The official regulatory profile for Бараклюд (Entecavir) indicates a low potential for drug-drug interactions via the hepatic metabolic pathway, as the drug is documented as neither a substrate, inhibitor, nor inducer of the Cytochrome P450 enzyme system.

The primary risk for a pharmacokinetic interaction involves the elimination route, as Entecavir is cleared predominantly by the kidneys through active tubular secretion. Co-administration with other medicines that reduce renal function or compete for this same active tubular secretion process may lead to increased serum concentrations—or higher drug exposure—for either Entecavir or the co-administered medicine. Interacting agents mentioned in regulatory documents include certain nucleoside analogues such as Lamivudine, Adefovir, and Tenofovir.

A significant interaction is documented with food: consumption with a meal causes a reduction in the drug's overall exposure (AUC and Cmax). To prevent this effect, the official label requires administration on an empty stomach, defined as taking the medicine at least two hours before or two hours after eating.

Finally, a specific population restriction notes that therapy with Entecavir is not recommended for patients co-infected with HIV and HBV who are not simultaneously receiving highly active antiretroviral therapy (HAART), due to the potential risk for the development of resistance to HIV nucleoside reverse transcriptase inhibitors.

Targeting the Core Viral Replication Enzyme

The drug's mechanism centers on becoming activated inside infected cells (hepatocytes) to target the Hepatitis B Virus ( HBV) DNA polymerase, a viral enzyme essential for reproduction. By acting as a specific competitive inhibitor of this key machinery, the drug engages mechanisms that regulate the virus's ability to create new genetic material.

Molecular Mechanism and Physiological Consequence

The active form of the drug initiates a cascade where it structurally mimics natural genetic building blocks. This competitive interaction leads to immediate DNA chain termination, which is the core pathway effect. This mechanism simultaneously shuts down all three enzymatic activities of the viral polymerase: base priming, reverse transcription, and positive-strand DNA synthesis. Engaging these multi-faceted inhibitory mechanisms results in a substantial decrease in the total amount of circulating viruses, a key physiological consequence of the drug's action.

How to Use Baraclude (Entecavir): Administration Guidelines

Baraclude (entecavir) is administered via the oral route and is available as film-coated tablets (0.5 mg and 1 mg) and an oral solution (0.05 mg/mL). The dosage and contextual rules for use define a once-daily administration schedule.

Standard Daily Dosing Regimens

The required dose depends on the patient's prior treatment history and the severity of their chronic Hepatitis B Virus (HBV) infection. The typical starting regimen for nucleoside-inhibitor-naïve adults and adolescents (aged 16 years and older) with compensated liver disease is 0.5 mg once daily. For adults and adolescents with lamivudine-refractory disease or decompensated liver disease, the prescribed dose is 1 mg once daily.

Administration Timing and Preparation

The timing of administration is dose-dependent: the 0.5 mg dose can be taken with or without food. However, the 1 mg dose must be taken on an empty stomach, meaning at least two hours after a meal and two hours before the next meal. Pediatric patients (aged 2 years and older and weighing at least 10 kg) receive weight-based dosing. Importantly, the oral solution must not be diluted or mixed with water or any other liquid.

Population-Specific Use and Duration

Dosage modification is required for patients with impaired renal function (Creatinine Clearance < 50 mL/min), including those on dialysis, but no adjustment is needed solely for hepatic impairment or older adults. Treatment is typically administered as a long-term, indefinite regimen, and discontinuation is not generally recommended for patients with advanced liver disease, such as cirrhosis or decompensated disease.

Evidence for Use in Chronic Hepatitis B Infection in Adults

The primary research for Entecavir was conducted through large, international Randomized Controlled Trials (RCTs). These are highly structured studies designed to evaluate its use against other treatments or a placebo under controlled conditions. This research was studied in populations of adults who were nucleos(t)ide-naïve (had not previously received similar antiviral treatments).

Studies report patterns where the measurement of HBV DNA levels became low or undetectable in the observed populations over the initial study duration, typically 48 to 96 weeks. Studies describe the measured changes in ALT levels (liver enzymes) that occurred in the observed populations. The evidence contributes to understanding symptom patterns by describing the rate at which certain viral activity markers changed.

However, many of the initial, pivotal RCTs compared Entecavir against antiviral agents that are no longer the most commonly used first-line treatments, which means comparative evidence against some current therapies is limited. Furthermore, the patient cohorts in the core studies were highly selected, suggesting that the results apply only to the populations studied and may not fully reflect outcomes in the broader, real-world population.

---

Evidence in Patients with Advanced Liver Disease (Cirrhosis)

Research examined Entecavir in patients with more advanced liver disease, specifically cirrhosis. Due to the complexity of this condition, the research strategy relied less on traditional controlled trials and more on Observational Cohort Studies that track real-world patient data over time. These studies were evaluated in patients with both compensated and decompensated cirrhosis.

Findings describe patterns observed in these studies, reporting that the stability of HBV DNA levels was monitored in these high-risk patients. Research examined outcomes monitoring physiological strain or stress, focusing on overall survival, transplant-free survival, and measured changes in clinical liver function scores.

---

Long-Term Research and Durability of Response

Studies have explored the long-term application of Entecavir over defined time intervals, with follow-up periods that can extend up to five, eight, and ten years. The primary focus of these extended observations was the study of how HBV DNA levels were tracked and the incidence of clinical events related to the liver over extended time intervals. Findings describe patterns observed in the studies where HBV DNA levels remained low or undetectable across large patient cohorts over these extended periods.

Key Studies & References

1. Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

Common questions about Бараклюд (FAQ)

Q: Is Baraclude a course of treatment or does it need to be taken constantly?

The optimal duration of treatment for chronic Hepatitis B infection is currently not known. However, official product information generally describes the treatment regimen as being long-term. For patients with advanced liver disease, such as decompensated cirrhosis, regulatory documents state that treatment discontinuation is officially not recommended.

Q: Can I consume small amounts of alcohol while taking Baraclude?

Official drug labels do not contain specific prohibitions regarding alcohol consumption. However, this medicine belongs to a class of drugs associated with a documented risk of Lactic Acidosis and severe liver events. Patients with other risk factors for liver disease are referenced in the official cautions regarding nucleoside analogues.

Q: Does Baraclude affect blood tests?

Yes, official clinical trial data indicates that Baraclude can cause changes in certain laboratory values. Common changes reported in blood test results include increases in liver enzymes (transaminases), as well as increased levels of Amylase and Lipase. Monitoring of these types of changes is usually described as part of the overall treatment process.

Q: Are there any age restrictions for elderly people?

There is no specific dosage adjustment required based on a patient's age alone. Official guidelines note that older patients are more likely to have reduced kidney function. Because the medicine is cleared by the body primarily by the kidneys, dose modifications are determined based on the individual's renal function.

Q: What does research say about the safety of Baraclude for children?

Official regulatory documents state that the medicine is approved for pediatric patients who are 2 years of age and older. It is noted, however, that specific studies on how the drug is handled by the body (pharmacokinetics) have not been conducted in children with existing kidney or liver impairment.

Q: Can there be a temporary worsening of condition in the beginning of taking it?

Official regulatory information describes that an on-treatment exacerbation, which is a temporary rise in liver enzymes (serum ALT), may occur in some patients. This reaction is generally observed during the initial weeks of therapy, often around 4 to 5 weeks after starting the medicine, as the viral load declines.

Q: Does Baraclude affect immunity?

Baraclude is classified as a Nucleoside Reverse Transcriptase Inhibitor (NRTI), which is a type of antiviral agent. Its use is officially restricted in patients who are co-infected with both HIV and HBV but are not receiving effective antiretroviral therapy (HAART). This restriction is due to the potential risk for the HIV virus to develop resistance to similar anti-HIV drugs.

Q: Why does Baraclude treatment sometimes last for years?

Treatment for chronic Hepatitis B is aimed at achieving and maintaining sustained viral suppression over time. Official treatment plans are administered until specific virological outcomes are met, such as HBe seroconversion. Because the condition is chronic and requires ongoing control of the virus, maintaining this suppression often requires treatment to continue for extended periods, sometimes lasting years.

Q: What is the role of Baraclude in preventing liver cancer?

The official product information states that the relationship between treatment with this medicine and long-term outcomes, specifically hepatocellular carcinoma (HCC) or liver cancer, is officially unknown. Clinical studies do, however, track the incidence of liver-related clinical events over extended time periods to gather such data.

Q: What happens if I accidentally take a double dose?

Official documents state there is limited experience with accidental overdosage of this medicine. In the event of accidental overdosage, monitoring for signs of toxicity is indicated, and standard supportive treatment should be given.

Q: How do I know that my body is reacting poorly to Baraclude?

Official safety warnings describe that symptoms suggesting Lactic Acidosis (a serious, rare side effect) may include nausea, vomiting, or abdominal pain. The development of these symptoms or pronounced signs of liver problems may necessitate a re-evaluation of treatment.

Q: What data is available on stopping treatment?

Discontinuation of treatment may be considered when the patient achieves specific virological outcomes, such as HBe seroconversion or HBs seroconversion. Safety data indicates that severe exacerbations of hepatitis have been reported after stopping therapy, and monitoring is typically continued after treatment ceases.

Q: Do I need to adjust Baraclude intake around other medications?

Caution is officially advised when taking Baraclude with other medicines that are also eliminated through the kidneys by a process called active tubular secretion. Combining such medicines could potentially increase the concentration of either drug in the blood. Dose adjustments for either drug may be determined by a healthcare provider in these circumstances.

Q: What serious but rare side effects are described in documents?

Official warnings describe two major serious adverse reactions associated with this class of drugs. One is the risk of a Severe Acute Exacerbation of Hepatitis B that may occur upon stopping the medicine. The second is the rare, but potentially fatal, risk of Lactic Acidosis and Severe Hepatomegaly with Steatosis (enlarged liver with fat build-up).

Official Storage and Disposal Requirements

Baraclude tablets and oral solution must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept away from excessive heat, light, and moisture; therefore, storage in locations like a bathroom cabinet is prohibited.

Storage Rule	Requirement
Container & Protection	Keep in the original outer carton and a tightly closed container.
Stability	Tablets in the HDPE bottle must be discarded 90 days after first opening.
Safety	Must be stored out of the reach and sight of children.

For disposal, the best option is a drug take-back program. If this is unavailable, unused tablets are specified for immediate disposal by flushing down the toilet. Any unused product or waste material must be handled according to local regulatory requirements.